Partner at Khosla Ventures
Check size: No personal check range is published. Jai focuses on growth-stage opportunities, while Khosla's Main Fund covers early through later-stage ventures and all total financings above $10M. Round size is not the same as Jai's personal allocation authority.
Jai looks for category-defining growth companies with the potential for outsized scale and economics, while remaining open to bold bets even after the early stage. His public-markets background adds an underwriting lens oriented toward durable revenue quality, market structure, capital efficiency, and the path to IPO and beyond. His disclosed work includes Slash, Omnea, Zetwerk, ClickHouse, Abridge, Vercel, Glean, Kiddom, and Even.
Show why the company is becoming the category leader: market size, product differentiation, retention, efficient growth, gross or contribution economics, competitive position, and a credible expansion path. Reconcile private-market ambition with the metrics a long-term public investor will eventually demand. Identify remaining risks, financing needs, and the operating partnership you want—not just the capital.
Category leaders with large markets, differentiated products, strong growth, and economics capable of supporting outsized scale. He values ambitious founders who want a deep operating partnership and can build a company that remains attractive under both private-market vision and public-market scrutiny.
The published focus implies weak fit for subscale growth stories, undifferentiated companies without category leadership, growth purchased with structurally poor economics, markets too small for an outsized outcome, and teams unable to explain the milestones and risks between today's business and a durable public company.
Underwrite a growth company by connecting its current product and customer evidence to durable revenue quality, market leadership, operating leverage, governance, and the milestones required for IPO-scale scrutiny.
Test market size, product differentiation, retention, unit economics, capital intensity, and expansion together; rapid growth matters only if the business can compound into an outsized and defensible outcome.
Do not equate growth stage with low risk or incrementalism: retain room for a technically or strategically bold bet when the evidence, team, and potential economics justify non-consensus conviction.
+ 142 more investments. View fund →